Irbesartan Recalled for Possible Cancer Risk
On October 31, 2018, the FDA announced a recall of Irbesartan after it was found to contain a probable human carcinogen called N-nitrosodiethylamine (NDEA).
Irbesartan, like Valsartan, is an angiotensin II receptor blocker. Since July, several drugs that contain valsartan have been recalled. Valsartan was recalled in July 2018 after NDMA was found to have contaminated the drug. Now Irbesartan was found to contain NDEA, a probable human carcinogen similar to NDMA. This contamination and recall of these “Sartan” drugs is the largest in FDA history.
The recalled Irbesartan was supplied by Aurobindo Pharma Limited to:
- ScieGen Pharmaceuticals labeled as Westminster Pharmaceuticals
- ScieGen Pharmaceuticals labeled as Golden State Medical Supply, Inc.
Exposure to NDMA and NDEA can cause:
- Liver Cancer
- Stomach Cancer
- Colon Cancer
- Intestinal Cancer
- Prostate Cancer (Must be diagnosed before age 60)
- Lower Esophageal Cancer
- Non-Hodgkin Lymphoma
- Multiple Myeloma
- Pancreatic Cancer
If you or a loved one contracted liver cancer, stomach cancer, colorectal cancer, intestinal cancer, esophageal cancer, prostate cancer, pancreatic cancer, non-hodgkin’s lymphoma, leukemia, or multiple myeloma after taking Irbesartan or Valsartan, please contact GoldenbergLaw, and leave the sleepless nights to us.